The present invention describes the use of a sesquiterpene compound for the treatment or prevention of primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject, preferably the compound (+)-elatol, and the pharmaceutical composition containing said compound.
High selectivity index
Low toxicity levels
An alternative to current treatments
Treatment for diseases caused by the "brain-eating amoeba"“ Naegleria fowleri